# TRAK-ER (NCT04985266)

> A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04985266
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Royal Marsden NHS Foundation Trust
- Conditions: ER+ Breast Cancer; HER2-negative Breast Cancer
- Interventions: Palbociclib 125Mg Tab; Fulvestrant injection; Tamoxifen; Letrozole; Exemestane; Anastrozole
- Enrollment: 1100
- Primary outcome: Incidence of positive ctDNA result during surveillance (Surveillance phase)
- Primary outcome: Incidence of positive ctDNA result at first test (Surveillance phase)
- Primary outcome: Relapse free survival (Treatment phase)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- Podcasts: 2
- YouTube: 1
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=trak-er-nct04985266

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04985266", "email": "<work email>"}; the inbox owner confirms by the emailed link.